CSIRO’s IP revenues on the up
05 August, 2004 by Graeme O'NeillCSIRO has reported sharp rise in intellectual property revenues 2003-04 financial year, to $22 million -- a 60 per cent increase on its 2003-03 figure of $13.75 million.
Circadian boasts $5.8m profit
02 August, 2004 by Melissa TrudingerCircadian Technologies (ASX:CIR) has posted a AUD$5.8 million profit for the 2003-04 financial year, and the prospects of an even better year next year thanks to the recent acquisition of its investee company Axon Instruments by US firm Molecular Devices on July 1.
Revenir raises $1.5 million, expects oversubscription
28 July, 2004 by Melissa TrudingerRevenir (ASX: REV) has achieved the first step in its proposed merger with British biotech company Bone with the raising of more than AUD$1.5 million in a share placement.
Genesis R&D subsidiary lays of half its staff
28 July, 2004 by Melissa TrudingerNew Zealand company Genesis R&D (NZX/ASX: GEN) has laid off more than half of the staff from its subsidiary AgriGenesis, due to a lack of success in raising capital for the spin-out company.
Up to his own devices: Alan Finkel on life after Axon
26 July, 2004 by Melissa TrudingerAsk Alan Finkel what he would do differently if he started another company, and he’s quick to reply. “I wouldn’t start another company overseas,” he says.
Amrad shareholders stock up
22 July, 2004 by Melissa TrudingerSome of Amrad's larger shareholders are boosting their holdings in the Melbourne company (ASX:AML), as long-time Japanese investor Chugai divests itself of its 10 per cent stake in the company.
Good Start for local businesses
22 July, 2004 by Iain ScottLife science companies - from start-ups to listed biotechs - featured highly in the latest round of Commonwealth R&D Start funding, it was revealed yesterday.
Few dauntless biotechs still queuing for IPOs
20 July, 2004 by Melissa TrudingerMixed results from recent IPOs in the Australian and international biotech sectors have not daunted several local biotechs' plans to list on the ASX in coming months.
PanBio raising restricted to $1m
16 July, 2004 by Melissa TrudingerA softening market and a low share price have had an impact on PanBio's (ASX:PBO) recently completed share purchase plan offering to shareholders, which has raised just under AUD$1 million out of a possible $4.2 million.
Lorne conferences move offshore
16 July, 2004 by Melissa TrudingerNext year's Lorne conferences, the traditional summer high point for Australian life science researchers, will not be held at Lorne.
Psivida wins technology award
15 July, 2004 by Melissa TrudingerNanotechnology company Psivida (ASX: PSD) has had its research applying its BioSilicon technology to drug delivery, diagnostics, orthopaedics and tissue engineering recognised with a 2004 Excellence in Research Award from US consulting group Frost & Sullivan.
Four of the best: pSiVida, Progen, AustCancer, Anadis
08 July, 2004 by Graeme O'NeillThree Australian biotechnology companies logged share price gains of over 300 per cent this financial year: pSivida (ASX: PSD) soared 387 per cent, Progen (ASX:PGL) was up 368 per cent and Australian Cancer Technology (ASX:ACU) was up 316 per cent. Biopharmaceutical company Anadis (ASX:ANX) also hit its stride, its share price rising 177 per cent.
Size isn't everything in nanotechnology
08 July, 2004 by Melissa TrudingerNanobiotechnology is one of the main opportunities for Australia to develop capabilities in nanotechnology, the CEO of Nanotechnology Victoria (Nanovic) Peter Binks said today.
Schofield leaves Garvan to join Prince of Wales
07 July, 2004 by Renate KrelleNeuroscience and mental illness specialist Prof Peter Schofield has been appointed executive director and CEO of the Prince of Wales Medical Research Institute, and plans to move his 15-strong research team from the Garvan Institute to yet-to-be-built labs in Sydney’s Randwick.
IDT scores Pfizer contract
05 July, 2004 by Melissa TrudingerThe Institute of Drug Technology (ASX: IDT) has scored a multi-million dollar contract with Pfizer to develop and manufacture a new drug candidate.
